Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics

  1. Natasha D Durham
  2. Aditi Agrawal
  3. Eric Waltari
  4. Derek Croote
  5. Fabio Zanini
  6. Mallorie Fouch
  7. Edgar Davidson
  8. Olivia Smith
  9. Esteban Carabajal
  10. John E Pak
  11. Benjamin J Doranz
  12. Makeda Robinson
  13. Ana M Sanz
  14. Ludwig L Albornoz
  15. Fernando Rosso
  16. Shirit Einav
  17. Stephen R Quake
  18. Krista M McCutcheon
  19. Leslie Goo  Is a corresponding author
  1. Chan Zuckerberg Biohub, United States
  2. Stanford University, United States
  3. Integral Molecular, Inc, United States
  4. Fundación Valle del Lili, Colombia
  5. Fred Hutchinson Cancer Research Center, United States

Abstract

Eliciting broadly neutralizing antibodies (bNAbs) against the four dengue virus serotypes (DENV1-4) that are spreading into new territories is an important goal of vaccine design. To define bNAb targets, we characterized 28 antibodies belonging to expanded and hypermutated clonal families identified by transcriptomic analysis of single plasmablasts from DENV-infected individuals. Among these, we identified J9 and J8, two somatically related bNAbs that potently neutralized DENV1-4. Mutagenesis studies showed that the major recognition determinants of these bNAbs are in E protein domain I, distinct from the only known class of human bNAbs against DENV with a well-defined epitope. B cell repertoire analysis from acute-phase peripheral blood suggested that J9 and J8 followed divergent somatic hypermutation pathways, and that a limited number of mutations was sufficient for neutralizing activity. Our study suggests multiple B cell evolutionary pathways leading to DENV bNAbs targeting a new epitope that can be exploited for vaccine design.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 4, and 6.

The following previously published data sets were used

Article and author information

Author details

  1. Natasha D Durham

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Aditi Agrawal

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Eric Waltari

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Eric Waltari, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
  4. Derek Croote

    Department of Bioengineering, Stanford University, Stanford, United States
    Competing interests
    Derek Croote, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4907-1865
  5. Fabio Zanini

    Department of Bioengineering, Stanford University, Stanford, United States
    Competing interests
    Fabio Zanini, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7097-8539
  6. Mallorie Fouch

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  7. Edgar Davidson

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  8. Olivia Smith

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Esteban Carabajal

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  10. John E Pak

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Benjamin J Doranz

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  12. Makeda Robinson

    Department of Medicine, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
  13. Ana M Sanz

    Clinical Research Center, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  14. Ludwig L Albornoz

    Pathology and Laboratory Department, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  15. Fernando Rosso

    Clinical Research Center, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  16. Shirit Einav

    Department of Medicine, Stanford University, Stanford, United States
    Competing interests
    Shirit Einav, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6441-4171
  17. Stephen R Quake

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Stephen R Quake, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1613-0809
  18. Krista M McCutcheon

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Krista M McCutcheon, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
  19. Leslie Goo

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    For correspondence
    lgoo@fredhutch.org
    Competing interests
    Leslie Goo, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3866-6735

Funding

Chan Zuckerberg Biohub

  • Natasha D Durham
  • Aditi Agrawal
  • Eric Waltari
  • Fabio Zanini
  • Olivia Smith
  • Esteban Carabajal
  • John E Pak
  • Stephen R Quake
  • Krista M McCutcheon
  • Leslie Goo

Fred Hutchinson Cancer Research Center

  • Leslie Goo

National Institutes of Health (HHSN272201400058C)

  • Benjamin J Doranz

NSF Graduate Research Fellowship

  • Derek Croote

Kou-I Yeh Stanford Graduate Fellowship

  • Derek Croote

Catalyst Award from Dr Ralph and Marian Falk Medical Research Trust

  • Shirit Einav

Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program

  • Shirit Einav

Stanford Advanced Residency Training at Stanford Fellowship Program

  • Makeda Robinson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the Stanford University Administrative Panel on Human Subjects in Medical Research (Protocol #35460) and the Fundación Valle del Lili Ethics committee in biomedical research (Cali, Colombia). All subjects, their parents, or legal guardians provided written informed consent, and subjects between 6 to 17 years of age and older provided assent.

Reviewing Editor

  1. Sara L Sawyer, University of Colorado Boulder, United States

Publication history

  1. Received: October 3, 2019
  2. Accepted: December 9, 2019
  3. Accepted Manuscript published: December 10, 2019 (version 1)
  4. Version of Record published: December 23, 2019 (version 2)

Copyright

© 2019, Durham et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,506
    Page views
  • 597
    Downloads
  • 23
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Natasha D Durham
  2. Aditi Agrawal
  3. Eric Waltari
  4. Derek Croote
  5. Fabio Zanini
  6. Mallorie Fouch
  7. Edgar Davidson
  8. Olivia Smith
  9. Esteban Carabajal
  10. John E Pak
  11. Benjamin J Doranz
  12. Makeda Robinson
  13. Ana M Sanz
  14. Ludwig L Albornoz
  15. Fernando Rosso
  16. Shirit Einav
  17. Stephen R Quake
  18. Krista M McCutcheon
  19. Leslie Goo
(2019)
Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics
eLife 8:e52384.
https://doi.org/10.7554/eLife.52384

Further reading

    1. Immunology and Inflammation
    Valentin Quiniou, Pierre Barennes ... David Klatzmann
    Research Article

    T-cell receptors (TCRs) are formed by stochastic gene rearrangements, theoretically generating >1019 sequences. They are selected during thymopoiesis, which releases a repertoire of about 108 unique TCRs per individual. How evolution shaped a process that produces TCRs that can effectively handle a countless and evolving set of infectious agents is a central question of immunology. The paradigm is that a diverse enough repertoire of TCRs should always provide a proper, though rare, specificity for any given need. Expansion of such rare T cells would provide enough fighters for an effective immune response and enough antigen-experienced cells for memory. We show here that human thymopoiesis releases a large population of clustered CD8+ T cells harboring α/β paired TCRs that (i) have high generation probabilities and (ii) a preferential usage of some V and J genes, (iii) which CDR3 are shared between individuals, and (iv) can each bind and be activated by multiple unrelated viral peptides, notably from EBV, CMV, and influenza. These polyspecific T cells may represent a first line of defense that is mobilized in response to infections before a more specific response subsequently ensures viral elimination. Our results support an evolutionary selection of polyspecific α/β TCRs for broad antiviral responses and heterologous immunity.

    1. Immunology and Inflammation
    Huaming Xu, Zhijian Li ... Martin Zenke
    Research Article Updated

    Transcription factors play a determining role in lineage commitment and cell differentiation. Interferon regulatory factor 8 (IRF8) is a lineage determining transcription factor in hematopoiesis and master regulator of dendritic cells (DC), an important immune cell for immunity and tolerance. IRF8 is prominently upregulated in DC development by autoactivation and controls both DC differentiation and function. However, it is unclear how Irf8 autoactivation is controlled and eventually limited. Here, we identified a novel long non-coding RNA transcribed from the +32 kb enhancer downstream of Irf8 transcription start site and expressed specifically in mouse plasmacytoid DC (pDC), referred to as lncIrf8. The lncIrf8 locus interacts with the lrf8 promoter and shows differential epigenetic signatures in pDC versus classical DC type 1 (cDC1). Interestingly, a sequence element of the lncIrf8 promoter, but not lncIrf8 itself, is crucial for mouse pDC and cDC1 differentiation, and this sequence element confers feedback inhibition of Irf8 expression. Taken together, in DC development Irf8 autoactivation is first initiated by flanking enhancers and then second controlled by feedback inhibition through the lncIrf8 promoter element in the +32 kb enhancer. Our work reveals a previously unrecognized negative feedback loop of Irf8 that orchestrates its own expression and thereby controls DC differentiation.